American Journal of Cardiovascular Drugs

, Volume 14, Issue 1, pp 15–29 | Cite as

Novel Oral Anticoagulants for Stroke Prevention in the Geriatric Population

  • Daniel Kim
  • Richard Barna
  • Mary Barna Bridgeman
  • Luigi Brunetti
Review Article


Prior to the availability of several newer anticoagulant medications, there had been no new advances in anticoagulation management for stroke prevention since the advent of warfarin in the 1950s. The availability of the novel oral anticoagulants (NOACs) dabigatran, rivaroxaban, and apixaban represent improvements over warfarin in many respects, including the elimination of the need for therapeutic drug monitoring, fewer drug and food interactions, and favorable efficacy; however, these agents are not without risk. Specifically, the use of the NOACs in the geriatric population, who are more likely to have an increased risk of stroke due to atrial fibrillation and other medical comorbidities, is not without risk. The objective of this review is to update the clinician on the use of the NOACs in the geriatric population and introduce the controversies and risks surrounding these newer therapies.



The authors report no funding was received for the preparation of this paper. The authors report no relevant conflicts of interest. The authors have no additional acknowledgements.


  1. 1.
    Kochanek KD, Xu JQ, Murphy SL, Minino AM, Kung HS. Deaths: preliminary data for 2009. Natl Vital Stat Rep. 2011;59(4).Google Scholar
  2. 2.
    Murphy SL, Xu JQ, Kochanek KD. Deaths: preliminary data for 2010. Natl Vital Stat Rep. 2012;60(4).Google Scholar
  3. 3.
    Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.PubMedCrossRefGoogle Scholar
  4. 4.
    Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Hall MJ, Levant S, DeFrances CJ. Hospitalization for stroke in U.S. hospitals, 1989–2009. NCHS Data Brief. 2012; (95):1–8.Google Scholar
  6. 6.
    Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: a general practice-based study. Br J Gen Pract. 2001;51(472):884–86, 9–91.Google Scholar
  7. 7.
    Langenberg M, Hellemons BS, van Ree JW, Vermeer F, Lodder J, Schouten HJ, et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ. 1996;313(7071):1534.PubMedCrossRefGoogle Scholar
  8. 8.
    Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34(7):489b–98b.CrossRefGoogle Scholar
  9. 9.
    Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.PubMedCrossRefGoogle Scholar
  10. 10.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S–47S.PubMedCrossRefGoogle Scholar
  12. 12.
    You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S–75S.PubMedGoogle Scholar
  13. 13.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27(3):373–80.PubMedGoogle Scholar
  16. 16.
    Hobbs FD, Roalfe AK, Lip GY, Fletcher K, Fitzmaurice DA, Mant J. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ. 2011;342:d3653.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Araujo I, Fonseca C, Cardiga R, Dores H, Ferreira R, Gandara F, et al. CHA2DS2-VASc and HASBLED scores: implications for thromboembolic prophylaxis in the elderly with atrial fibrillation. Eur Geriatr Med. 2013;4:67–72.CrossRefGoogle Scholar
  18. 18.
    Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56(11):827–37.PubMedCrossRefGoogle Scholar
  19. 19.
    Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010;8(10):2105–12.Google Scholar
  20. 20.
    Zhao CS, Hartikainen S, Schallert T, Sivenius J, Jolkkonen J. CNS-active drugs in aging population at high risk of cerebrovascular events: evidence from preclinical and clinical studies. Neurosci Biobehav Rev. 2008;32(1):56–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc. 2010;58(9):1749–57.PubMedCrossRefGoogle Scholar
  22. 22.
    Baltan S, Besancon EF, Mbow B, Ye Z, Hamner MA, Ransom BR. White matter vulnerability to ischemic injury increases with age because of enhanced excitotoxicity. J Neurosci. 2008;28(6):1479–89.PubMedCrossRefGoogle Scholar
  23. 23.
    Riva N, Smith DE, Lip GY, Lane DA. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. Age Ageing. 2011;40(6):653–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing. 2011;40(6):675–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfounded. Arch Intern Med. 2003;163(13):1580–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927–34.PubMedCrossRefGoogle Scholar
  27. 27.
    Khaw KT, Barrett-Connor E, Suarez L, Criqui MH. Predictors of stroke-associated mortality in the elderly. Stroke. 1984;15(2):244–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395–401.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.PubMedCrossRefGoogle Scholar
  30. 30.
    Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60(9):861–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;143(1):179–84.PubMedCrossRefGoogle Scholar
  34. 34.
    van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost. 1996;76(1):12–6.PubMedGoogle Scholar
  35. 35.
    Pengo V, Legnani C, Noventa F, Palareti G. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost. 2001;85(3):418–22.PubMedGoogle Scholar
  36. 36.
    Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348(9025):423–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging. 1999;14(4):303–12.PubMedCrossRefGoogle Scholar
  38. 38.
    A Profile of Older Americans: 2012. Administration on Aging; Administration for Community Living; US Department of Health and Human Services. 2012. Available from: Accessed 16 Oct 2013.
  39. 39.
    Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging. 1999;14(3):231–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57(2):121–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–25.PubMedCrossRefGoogle Scholar
  42. 42.
    Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31(4):199–205.PubMedCrossRefGoogle Scholar
  43. 43.
    Hofer-Dueckelmann C, Prinz E, Beindl W, Szymanski J, Fellhofer G, Pichler M, et al. Adverse drug reactions (ADRs) associated with hospital admissions—elderly female patients are at highest risk. Int J Clin Pharmacol Ther. 2011;49(10):577–86.PubMedCrossRefGoogle Scholar
  44. 44.
    Mannesse CK, Derkx FH, de Ridder MA, Man in ‘t Veld AJ, van der Cammen TJ. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing. 2000;29(1):35–9.Google Scholar
  45. 45.
    Olivier P, Bertrand L, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey. Drugs Aging. 2009;26(6):475–82.PubMedCrossRefGoogle Scholar
  46. 46.
    Conforti A, Costantini D, Zanetti F, Moretti U, Grezzana M, Leone R. Adverse drug reactions in older patients: an Italian observational prospective hospital study. Drug Healthc Patient Saf. 2012;4:75–80.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147(11):755–65.PubMedCrossRefGoogle Scholar
  48. 48.
    Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–41.PubMedCrossRefGoogle Scholar
  49. 49.
    Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–53.PubMedCrossRefGoogle Scholar
  50. 50.
    Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J. 2011;32(16):1968–76, 76a.Google Scholar
  51. 51.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.PubMedCrossRefGoogle Scholar
  52. 52.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.PubMedCrossRefGoogle Scholar
  53. 53.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.PubMedCrossRefGoogle Scholar
  54. 54.
    Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–41.PubMedCrossRefGoogle Scholar
  55. 55.
    Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012.Google Scholar
  56. 56.
    Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436–50.PubMedCrossRefGoogle Scholar
  57. 57.
    Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47–59.PubMedCrossRefGoogle Scholar
  58. 58.
  59. 59.
  60. 60.
    Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012;52(9):1373–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol. 2012;52(1 Suppl):119S–25S.PubMedCrossRefGoogle Scholar
  62. 62.
    Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106(5):868–76.PubMedCrossRefGoogle Scholar
  63. 63.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72.PubMedCrossRefGoogle Scholar
  64. 64.
    Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Sipahi I, Celik S, Akyol A. Dabigatran’s ‘real-world’ data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials. J Am Coll Cardiol. 2013;62(10):945–6.Google Scholar
  66. 66.
    Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, et al. Reply: Dabigatran’s ‘real-world’ data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials. J Am Coll Cardiol. 2013;62(10):946–7.Google Scholar
  67. 67.
    Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61(22):2264–73.PubMedCrossRefGoogle Scholar
  68. 68.
    Weitz JI, Gross PL. New oral anticoagulants: which one should my patient use? Hematol Am Soc Hematol Educ Program. 2012;2012:536–40.Google Scholar
  69. 69.
    Eikelboom JW, Weitz JI. Anticoagulation therapy. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol. 2012;9(5):260–2.PubMedCrossRefGoogle Scholar
  70. 70.
    Gelbricht V, Werth S, Koehler C, Haensel U, Tittl L, Beyer-Westendorf I, et al. Real life efficacy and safety of dabigatran for stroke prevention in atrial fibrillation—first results of the prospective Noac registry. Blood. 2012: Abstract 502.Google Scholar
  71. 71.
    Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Bene J, Said W, Rannou M, Deheul S, Coupe P, Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46(6):e14.PubMedCrossRefGoogle Scholar
  73. 73.
    Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost. 2012;108(3):583–5.PubMedCrossRefGoogle Scholar
  74. 74.
    No authors listed. Bleeding with dabigatran (Pradaxa). Med Lett Drugs Ther. 2011;53(1379–1380):98.Google Scholar
  75. 75.
    Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46(4):e10.PubMedCrossRefGoogle Scholar
  76. 76.
    Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med. 2012;157(1):66–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171(14):1285–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272–4.PubMedCrossRefGoogle Scholar
  79. 79.
    Berger R, Salhanick SD, Chase M, Ganetsky M. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med. 2013;61(4):475–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3(5):e002758.Google Scholar
  81. 81.
    Xarelto [package insert]. Titusville: Janssen Pharmaceuticals, Inc.; 2013.Google Scholar
  82. 82.
    Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm. 2008;65(16):1520–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24(10):2757–65.PubMedCrossRefGoogle Scholar
  84. 84.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412–21.PubMedCrossRefGoogle Scholar
  85. 85.
    Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26(1):27–32.PubMedCrossRefGoogle Scholar
  86. 86.
    Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–94.PubMedCrossRefGoogle Scholar
  87. 87.
    Kubitza D, Becka M, Mueck W. The effect of extreme age, and gender on the pharmacology and tolerability of rivaroxaban, an oral direct factor Xa inhibitor. Blood. 2006;108:Abstract 905.Google Scholar
  88. 88.
    Nutescu E. Apixaban: a novel oral inhibitor of factor Xa. Am J Health Syst Pharm. 2012;69(13):1113–26.PubMedCrossRefGoogle Scholar
  89. 89.
    Eliquis [package insert]. Princeton: Bristol-Meyers Squibb Co; 2012.Google Scholar
  90. 90.
    Frost CE, Nepal S, Barrett YC, LaCreta F. Effects of age and gender on the singledose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J Thromb Haemost. 2009;7(suppl 2):PP-MO-407 Abstract.Google Scholar
  91. 91.
    Frost CE, Yu Z, Wang J. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther. 2009;85(suppl 1):S34 Abstract.Google Scholar
  92. 92.
    Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol. 2013;75(4):966–78.PubMedCrossRefGoogle Scholar
  93. 93.
    Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012;76(8):1840–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):257S–98S.PubMedCrossRefGoogle Scholar
  95. 95.
    Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676–81.PubMedCrossRefGoogle Scholar
  96. 96.
    Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract. 2013;26(3):264–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila). 2012;50(9):854–7.CrossRefGoogle Scholar
  98. 98.
    Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009;136(4):1128–33.PubMedCrossRefGoogle Scholar
  99. 99.
    Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625–35.PubMedCrossRefGoogle Scholar
  100. 100.
    Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis. 2010;17(5):420–7.PubMedCrossRefGoogle Scholar
  101. 101.
    Remuzzi G, Marchesi D, Livio M, Cavenaghi AE, Mecca G, Donati MB, et al. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thromb Res. 1978;13(6):1007–15.PubMedCrossRefGoogle Scholar
  102. 102.
    Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20(4):912–21.PubMedCrossRefGoogle Scholar
  103. 103.
    McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med. 1998;13(5):311–6.PubMedCentralPubMedCrossRefGoogle Scholar
  104. 104.
    Saydah S, Eberhardt M, Rios-Burrows N. Prevalence of chronic kidney disease and associated risk factors—United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007;56(8):161–5.Google Scholar
  105. 105.
    Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122–37.PubMedCrossRefGoogle Scholar
  106. 106.
    Spruill WJ, Wade WE, Cobb HH 3rd. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother. 2008;6(3):153–60.PubMedCrossRefGoogle Scholar
  107. 107.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51.PubMedCrossRefGoogle Scholar
  108. 108.
    Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-14Google Scholar
  109. 109.
    Ukena C, Bohm M, Schirmer SH. Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more. Clin Res Cardiol. 2012;101(11):861–74.PubMedCrossRefGoogle Scholar
  110. 110.
    Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61(3):487–9.PubMedCrossRefGoogle Scholar
  111. 111.
    Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012;126(20):2428–32.PubMedCrossRefGoogle Scholar
  112. 112.
    van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27.PubMedCrossRefGoogle Scholar
  113. 113.
    Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131–6.PubMedCrossRefGoogle Scholar
  114. 114.
    Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23(3):264–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13):1168–74.PubMedCrossRefGoogle Scholar
  116. 116.
    Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J. 2012;76(10):2337–42.PubMedCrossRefGoogle Scholar
  117. 117.
    Takahashi N. Can dabigatran be an alternative periprocedural anticoagulation for atrial fibrillation ablation? Circ J. 2012;76(10):2327–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Daniel Kim
    • 1
  • Richard Barna
    • 2
  • Mary Barna Bridgeman
    • 1
    • 3
  • Luigi Brunetti
    • 1
    • 4
  1. 1.Department of Pharmacy Practice and Administration, Ernest Mario School of PharmacyRutgers, The State University of New JerseyPiscatawayUSA
  2. 2.Partners Pharmacy of New JerseyCranfordUSA
  3. 3.Robert Wood Johnson University HospitalNew BrunswickUSA
  4. 4.Somerset Medical CenterSomervilleUSA

Personalised recommendations